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Hepatocellular carcinoma (HCC) is themost common
primary liver cancer and the second most frequent
cause of cancer-related mortality worldwide. The
multikinase inhibitor sorafenib is the only treatment
option for advanced HCC. Due to tumor heterogene-
ity, its efficacy greatly varies between patients and is
limited due to adverse effects and drug resistance.
Current in vitro models fail to recapitulate key fea-
tures of HCCs. We report the generation of long-
term organoid cultures from tumor needle biopsies
of HCC patients with various etiologies and tumor
stages. HCC organoids retain the morphology as
well as the expression pattern of HCC tumor markers
and preserve the genetic heterogeneity of the origi-
nating tumors. In a proof-of-principle study, we
show that liver cancer organoids can be used to
test sensitivity to sorafenib. In conclusion, organoid
models can be derived from needle biopsies of liver
cancers and provide a tool for developing tailored
therapies.INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common primary
liver cancer, accounting for 90% of all liver cancers, and is the
second most frequent cause of cancer-related mortality world-
wide (Marquardt et al., 2015). Main risk factors include infection
with hepatitis B virus, hepatitis C virus, alcoholic liver disease,
nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis.
Intrahepatic cholangiocellular carcinoma (CCC) represents the
second most common primary liver cancer with main risk factors
including primary sclerosing cholangitis, cysts of the biliary duct,
and parasitic infection with liver flukes (Marquardt et al., 2015).
Currently available treatment options for HCC are unsatisfac-
tory. In the past, conventional chemotherapies have been exten-
sively tested, but none of them have improved survival (Chen
et al., 2015). Major progress came with the introduction of the
multikinase inhibitor sorafenib in 2008. In a landmark trial, sorafe-Cell
This is an open access article under the CC BY-Nnib was found to significantly prolong median survival from 7.9 in
the control group to 10.7 months in the sorafenib treatment group
(Llovet et al., 2008). In the following years >10 additional targeted
drugs were tested, but all failed to meet clinical endpoints in
phase III trials (Llovet and Hernandez-Gea, 2014). More recently,
the sorafenib derivative regorafenib (Bruix et al., 2017) and the im-
mune-checkpoint inhibitor nivolumab (El-Khoueiry et al., 2017)
showed efficacy in second-line treatments for advanced HCC.
However, given the limited efficacy of current HCC treatment op-
tions, there is an urgent need for new therapies for HCC.
A major obstacle in preclinical drug development is the lack of
appropriate cell culture model systems. Current in vitro cell cul-
ture models of HCC are based on conventional hepatoma and
hepatocarcinoma cell lines that fail to recapitulate key features
of tumor tissues such as three-dimensional tumor architecture,
cellular heterogeneity, and cell-cell interactions. The recently
developed organoid technology could overcome these limita-
tions because it allows differentiation of tissue stem cells into
functional organ-like structures (Clevers, 2016). Indeed, the gen-
eration of three-dimensional organoid cultures from patient-
derived tumors has been a major breakthrough in cancer
biology. Over the past 3 years, tumor-derived organoids have
been described for prostate (Gao et al., 2014), pancreatic (Boj
et al., 2015), colorectal (van de Wetering et al., 2015), breast
(Sachs et al., 2018), and bladder cancers (Lee et al., 2018).
In this study, we report the successful generation of tumor or-
ganoid cultures fromneedle biopsies obtained frompatients with
HCC. We demonstrate that HCC organoids recapitulate the his-
tological features of the originating tumor in vitro. Moreover, in-
jection of HCC organoids into immunodeficient mice results in
the formation of tumors that also recapitulate the histological
features of the original biopsy. Additionally, we show that HCC
organoids maintain the genomic features of their originating tu-
mors during long-term culturing for up to 32 weeks. Finally, we
demonstrate that HCC organoids respond to sorafenib treat-
ment with variable sensitivity.RESULTS
Establishment of HCC Organoid Cultures
We obtained tumor and non-tumor liver samples from patients
undergoing diagnostic needle biopsies for suspected HCCsReports 24, 1363–1376, July 31, 2018 ª 2018 The Author(s). 1363
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Establishment of Organoid Cul-
tures from Needle Biopsies of Hepatocellu-
lar Carcinoma and Paired Non-tumor Liver
Tissues
(A) Schematic workflow of organoid generation
from needle biopsies.
(B) Representative biopsy pieces of tumor and
liver tissue used for organoid generation.
(C) Representative bright-field images of tumor
and paired non-tumor liver tissue organoids from
three different patients. Tumor organoids form
compact spheroids, whereas liver organoids from
non-tumor liver tissue grow as cystic structures.
Organoids were imaged at the indicated passage
numbers. Scale bar: 500 mm.(Figures 1A and 1B). Biopsies were performed under ultrasound
guidance using a coaxial needle biopsy technique that allows for
obtaining up to five samples from the same location in a tumor
(described in the Experimental Procedures). This multiple
sampling procedure allowed a comprehensive characterization
of all samples by histopathology for clinical diagnosis and
Edmondson staging (Edmondson and Steiner, 1954), by immu-
nohistochemical staining to identify tumor markers, and by
whole-exome sequencing and RNA sequencing (RNA-seq) for
molecular analysis. In total, we established 10 HCC-derived or-
ganoid lines from eight patients (Table 1). For patient 5, we
generated organoid lines from two different tumor nodules (5-A
and 5-B). For patient 12, we established two tumor organoid
lines from two different locations of the same large tumor nodule
(12-I and 12-II; Table 1). We also established organoid cultures
from non-tumor liver biopsies in all patients (Figures 1C and
S1A; Table S1). HCC organoids present morphologically as
compact spheroids without a lumen but occasionally forming
pseudoglands (Figure 1C), whereas non-tumor liver-derived or-
ganoids, originating from cholangiocytes, grow as single-cell
layered cysts resembling the ductal epithelium (Huch et al.,
2015) (Figure S1A). The underlying disease spectrum of our pa-
tient cohort encompasses the major risk factors for HCC, viral
hepatitis, nonalcoholic fatty liver disease (NAFLD), and alcoholic
liver disease (ALD) (Table 1). Furthermore, the cohort represents
all different clinical stages of HCC according to the Barcelona
Clinic Liver Cancer (BCLC) staging system (Llovet et al., 1999)
(Table 1).1364 Cell Reports 24, 1363–1376, July 31, 2018The success rate for the generation of
HCC organoids was 26% based on the
number of cultured tumor biopsies (10
out of a total of 38 HCC biopsies). HCC
organoids were obtained in 8 of the 24
HCC patients included in the study
(33%) (Table S1). We did not find a corre-
lation between a number of clinically
relevant patient characteristics and the
success or failure to generate HCC orga-
noids from their tumors (Figure 2A). On
the other side, there was a strong correla-
tion with the histopathological grading of
the HCCs: all HCC organoids are derivedfrom poorly differentiated tumors (Edmondson grades III and IV)
(Figure 2A; Table 1). Furthermore, KI-67 staining of tumor bi-
opsies showed significantly higher cancer cell proliferation rates
in samples that could be propagated as tumor organoids
compared with samples that failed (Figures S2A and S2B).
The transcriptome data of the tumor biopsies were used to
analyze the distribution of our samples within a reference set
from The Cancer Genome Atlas (TCGA) (Cancer Genome Atlas
Research Network, 2017) using an unsupervised hierarchical
clustering analysis. Overall, our samples distributed evenly in
the entire reference dataset, but the eight samples from which
we could derive HCC organoids preferentially located in a sub-
class located at the left end of the clustering tree (Figure 2B).
Because all of our HCC organoids originated from poorly differ-
entiated HCCs (Edmondson grades III and IV), we also per-
formed the clustering analysis using the subset of poorly differ-
entiated HCCs from TCGA HCC database as a reference. In
this analysis, our samples distributed over the entire spectrum
of the tree (Figure 2C).We conclude that the organoidmodel sys-
tem strongly selects for Edmondson grade III and IV HCCs, but
within this group of poorly differentiated HCCs, there seems to
be no further selection of a specific molecular subtype.
HCC Organoids Recapitulate the Histopathological
Characteristics of the Originating Tumor
To investigate whether the histological characteristics of the
originating tumors were preserved in the HCC organoids,
two expert pathologists with expertise in hepatopathology
Table 1. HCC and CCC Patient Data Table
Patient Biopsy ID Sex Age (Years) Tumor Liver Disease(s) Cirrhosis BCLC Edmondson Growth Pattern AFP (IU/mL)
1 C655 male 55 HCC HCV; ALD no C III trabecular-pseudoglandular 269
2 C798 male 73 HCC NAFLD no C III solid-trabecular 20’377
5-A C948 male 57 HCC HCV; ALD yes C III trabecular 120054
5-B C949 III trabecular
9 C975 male 59 HCC HCV; ALD yes B III solid 250
12-I D045 male 69 HCC HCV no A III solid-trabecular 7’852
12-II D046 III solid-trabecular
13 D091 female 61 CCC none no – – – 4.4
16 D141 male 59 LELCC HBV yes – – – 2.1
20 D178 female 63 CCC none no – – – 3.1
25 D324 male 58 HCC HCV yes D III solid-trabecular 104’710
27 D359 male 86 HCC NAFLD no A III trabecular 5’917
29-A D386 male 80 HCC ALD; NAFLD no A IV solid 49.8
Clinical staging was done according to the Barcelona Clinic Liver Cancer (BCLC) staging system (Llovet et al., 1999). Serum alpha-fetoprotein (AFP)
concentrations were obtained from the clinical charts of the patients. Edmondson grade (Edmondson and Steiner, 1954) and the growth pattern were
determined in each biopsy on H&E-stained sections by two experienced hepato-pathologists (M.S.M. and L.M.T.). All CCC tumors were poorly differ-
entiated. AFP, alpha-fetoprotein; ALD, alcoholic liver disease; BCLC, Barcelona Clinic Liver Cancer; CCC, cholangiocellular carcinoma; HBV, hepatitis
B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LELCC, lymphoepithelioma-like cholangiocarcinoma; NAFLD, nonalcoholic fatty liver
disease.performed histological analysis and diagnostic evaluation on
the original biopsies and their tumor organoids on paraffin-
embedded sections. Notably, HCC organoids maintained the
growth pattern and differentiation grade of the originating
primary tumors (Figure 3A). For example, HCC organoids
derived from patient 2 displayed a solid growth pattern with an
Edmondson differentiation grade III as in the originating tumor
(Figure 3A). Likewise, tumor organoids from patient 12 formed
pseudoglands (Figure 3A), a feature that was also present in
the original HCC of this patient. Importantly, long-term culturing
up to 1 year did not alter the histological properties of the HCC
organoids (Figure S1B). As expected, immune cell infiltrates
and tumor stromal cells were not propagated in the organoids.
Wenext assessedwhether the expression of alpha-fetoprotein
(AFP), a tumor marker for HCC (Table 1), was maintained in the
corresponding organoids. Immunohistochemical analysis re-
vealed consistent distribution and expression intensity of AFP
between organoids and their original tumor biopsy tissue (Fig-
ure 3B). The same was true for three additional biomarkers
commonly used for histological HCC diagnosis, Glypican 3,
glutamine synthetase, and heat shock protein 70 (GPC3, GS,
andHSP70, respectively) (Di Tommaso et al., 2009) (Figure S1C).
Someof theHCCsalso stainedpositive for thebiliary cellmarkers
Keratin 7 (KRT7) andKeratin 19 (KRT19). Again, the expression of
these markers was maintained in the organoids (Figure 3C).
Taken together, these results demonstrate that HCC organoids
retain the phenotypic characteristics of their originating tumors.HCC Organoids Give Rise to Tumors upon Injection into
Immunodeficient Mice
To assess whether HCC organoids retained the ability to form
bona fide tumors in mice, we injected HCC organoids subcuta-
neously into immunodeficient mice. So far, 6 of the 10 HCC orga-noids could be stably propagated in mice (Figures 4A and 4D).
Two organoids failed to grow despite repeated transplantations.
Two organoidswere injected recently and the outcome could not
yet be determined (Figure 4D). Of note, all successfully trans-
planted organoids gave rise to xenograft tumors that recapitu-
lated the histopathological features and the tumor marker
expression (Figure 4B) of the originating organoids and the orig-
inal tumors. In contrast, and as expected, none of the paired
non-tumor liver organoids gave rise to neoplasms.
HCC Organoids Retain the Somatic Genetic Alterations
of the Originating Tumor
To assess whether the HCC organoids recapitulate the genetic
alterations of the originating tumor, we subjected DNA from
seven HCC organoid lines, their originating tumor biopsies,
as well as the paired non-tumor biopsies to whole-exome
sequencing (WES). WES was performed to median depths of
853, 953, and 503 in the organoids, biopsies, and non-tumor
counterparts, respectively (Table S2). The number of somatic
mutations in organoids (median 165, range 117–180) did not
significantly differ from that of the corresponding tumor biopsies
(median 146, range 127–207; p = 0.78, Mann-Whitney U test;
Table S3).
Of the total somatic and the subgroup of non-synonymous so-
matic mutations found in the HCC biopsies, a median of 88%
and 90%, respectively, was observed in the corresponding
HCC organoids at early passage of culturing (P3–P4) (Figures
5A, S3, and S4; Tables S3 and S4). Similar proportions (all so-
matic: 86%; non-synonymous somatic: 88%) were observed in
three representative cases where late-passage HCC organoids
(RP8) were profiled (Figures S3 and S7A; Tables S3 and S4).
Nearly all non-synonymous somatic mutations in bona fide can-
cer genes, including all of those in TP53 (p.Arg209fs in patient 2,Cell Reports 24, 1363–1376, July 31, 2018 1365
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Figure 3. Histopathological Characteristics of HCC and CCC Organoids and Their Primary Tumors
(A) Histological sections of HCC and CCC organoids and their original tumors stained with H&E. The originating tumors display primarily a solid-trabecular
architectural pattern with poor differentiation (Edmondson grades III and IV), features that are maintained in the corresponding HCC organoids. Arrowheads
indicate pseudoglandular structures in HCC organoids and intracytoplasmic lumen in CCC organoids.
(B) AFP expression detected by immunohistochemistry on organoids and original biopsies.
(C) Expression of biliary markers KRT7 and KRT19 detected by immunohistochemistry on organoids and original biopsies. Organoids were imaged at the
indicated passage numbers.
Scale bars: 100 mm.hotspot p.Arg342* in patient 9, and p.Val157Phe in patient 12-II),
ARID1A (c.5125-2A > T in patients 5-A and 5-B), CTNNB1
(hotspot p.Ser45Ala and p.Arg528Cys in patients 5-A and 5-B),
TSC1 (p.Gln767* in patient 2), and LRP1B (p.Cys2903Arg in
patient 9), were found in the organoids at both early and late
passages (Figures 5B, S3, and S7B). Of all the non-synonymous
mutations in bona fide cancer genes, only two were lost in the
corresponding HCC organoid (BRD7 p.Phe340Ile in patient 9;Figure 2. Clinical, Histopathological, and Molecular Features of HCC B
(A) Color-coded table of patient characteristics of all biopsies (n = 38) used for or
growth pattern were determined in each biopsy on H&E-stained sections by tw
extracted from the electronic patient information system of the hospital. Of not
organoid generation (p = 0.01, Fisher’s exact test, two-sided). For the Edmondson
were calculated per patient. ALD, alcoholic liver disease; AFP, alpha-fetoprotein;
virus; MVI, macrovascular invasion; NAFLD, nonalcoholic fatty liver disease.
(B and C) Unsupervised hierarchical clustering analysis.
(B) Biopsy (organoid) cohort (this study) combined with all HCCs from TCGA coh
(C) Biopsy (organoid) cohort (this study) combined with high-grade (EdmondsonARHGAP35 p.Glu1273Ala in patient 12-I). However, these muta-
tions were subclonal in the originating HCC biopsies (Figures
S3D and S4A), have not been previously reported in HCC, and
are predicted to be passenger mutations (Table S4). Overall,
we identified a median of 19 (range 8–29) and 14 (range 5–24)
novel somatic and non-synonymous somatic mutations in the
HCC organoids that were not present in the originating biopsies,
representing amedian of 15% and 12%of themutations presentiopsies Used for Organoid Generation
ganoid generation. Edmondson grade (Edmondson and Steiner, 1954) and the
o experienced hepato-pathologists (M.S.M. and L.M.T.). Clinical data were
e, only the Edmondson grade III was a significant determinant of successful
grade, calculations were performed per biopsy, whereas all other parameters
BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; HCV, hepatitis C
ort.
grades III and IV) HCCs from TCGA cohort.
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Figure 4. Histological Analysis of Xenografts Derived from HCC and CCC Organoids
(A) Growth curves of the xenograft tumors.
(B) Histological sections of xenograft tumors derived from HCC and CCC organoids stained with H&E. The HCC marker AFP and the biliary marker KRT7 were
detected by immunohistochemistry. Scale bar: 100 mm.
(C) Trichrome and Alcian blue-PAS staining on biopsy, derivative organoids, and xenograft of patient 20. Collagen-rich areas representing the desmoplastic
stroma reaction are colored in blue in Trichrome-stained sections. Mucin production appears light blue in sections stained with Alcian blue-PAS (arrowheads).
Organoids were imaged at the indicated passage numbers. Scale bars: 100 mm.
(D) Statistics of the xenograft experiments.in the HCC organoids, respectively. Most of these novel muta-
tions did not occur in bona fide cancer genes. Indeed, in four
of the seven tumor organoid lines, no additional non-synony-
mous mutations in cancer genes were identified. In patient1368 Cell Reports 24, 1363–1376, July 31, 20185-A, an ASXL1 mutation was found in both early- and late-pas-
sage HCC organoids, a PDGFRA mutation was found only in
the early passage, and an AXIN2 mutation only in the late pas-
sage, but not in the originating HCC biopsies (Figures 5B and
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S7B). However, 23%–46% of the organoid-specific mutations
were present in both early- and late-passage organoids origi-
nating from patient 2, patient 5-A, and patient 5-B (Table S3),
strongly suggesting that a substantial proportion of the HCC or-
ganoid-specific mutations were likely present in the originating
tumors at low frequencies, rather than being genuinely novel.
A detailed analysis of the cancer cell fraction (CCF) of the
somatic mutations (i.e., the proportion of cancer cells harboring
a given genetic alteration) between the organoid cultures
and their matched originating tumor indicated that both
harbored subclonal mutations (Figures 5C and S3–S6). For
example, we observed similar extents of intratumor heterogene-
ity between the biopsies and organoids of patient 5 (Figures 5C
and S3–S6). This has been previously observed in colorectal
cancer organoids (van de Wetering et al., 2015) and is likely to
be a genuine advantage of organoid cultures compared with
cancer cell lines.
Copy number analysis showed that most amplifications
were preserved in HCC organoids, and the overall patterns
of copy number alterations were similar between the biopsies
and the derivative HCC organoids at early and late passage
(Figures S7C and S7D). For instance, the amplifications of
chr1q21.3 (encompassing MCL1, SETDB1, ARNT, and
MLLT11) in patient 5 (A and B), 8q24.13-24.23 (MYC and
NDRG1) in patient 2, and 11q13.2-13.4 (CCND1, FGF19,
FGF4, and FGF3) in patient 12-II were all found in their corre-
sponding organoids. However, the heterogeneity observed at
mutational level was also present at the copy number alter-
ation (CNA) level. In fact, an amplification on 18q12.2
restricted to the HCC biopsy of patient 9, but not seen in
the respective HCC organoids and two amplifications on
19q12 (CCNE1) and 19q13.2 (MAP3K10 and AKT2), was found
only in the derivative HCC organoids.
We next investigated whether the biological and chemical pro-
cesses that shape the mutational landscape were maintained in
the organoid cultures. The analysis of the mutational signatures
demonstrated that the mutational landscape of the HCC bi-
opsies and the organoids was largely driven by mutational pro-
cesses associated with signatures 1 (associated with aging), 3
(homologous recombination DNA repair deficiency), 6 (mismatch
repair deficiency), and 16 (previously found in liver cancer with
unknown etiology) (Alexandrov et al., 2013) (Figure S8). The
mutational signatures were remarkably consistent between the
organoids and the originating HCC biopsies. These results sug-
gest that themutational processes that drive tumor development
were maintained in the organoids. Of note, the same patterns of
mutational signatures were also maintained in late-passage or-
ganoids (Figure S8).Figure 5. Repertoire of Genetic Alterations Found in the HCC and CCC
(A) Venn diagrams illustrate the number of somatic non-synonymous mutations pr
denotes CCC-derived tumors and corresponding organoids.
(B) Repertoire of somatic non-synonymous mutations affecting cancer genes (Fuj
Atlas Research Network, 2017). The effects of the mutations are color-coded acco
in red. Multiple non-synonymous mutations in the same gene are indicated by a
represented by a diagonal bar, and mutations found to be clonal by ABSOLUTE
(C) Contour plots illustrate the distribution of the cancer cell fractions (CCFs) of
increasing shades of red indicating higher number of somatic mutations at a give
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organoids derived from tumor biopsies largely maintain the ge-
netic alterations and mutational signatures observed in their
originating HCCs. Importantly, mutations and amplifications
affecting bona fide cancer genes found in the biopsies were pre-
served in the organoids. Furthermore, in line with previously pub-
lished reports (Lee et al., 2018; van de Wetering et al., 2015),
each HCC organoid line retained a remarkable intratumoral
mutational heterogeneity.
Generation of Organoids from Intrahepatic CCCs
In our consecutive series of patients with suspected primary liver
cancer who had a diagnostic needle biopsy (Table S1) therewere
four cases of intrahepatic CCCs and one case of a rare variant of
CCC, a lymphoepithelioma-like cholangiocarcinoma. All five
cases were poorly differentiated CCCs. In three cases we suc-
cessfully established CCC-derived tumor organoids. Morpho-
logically, CCC organoids resembled HCC organoids and formed
compact spheroids (Figures 1C and 3A), whereas the corre-
sponding non-tumor liver organoids formed single-cell layered
epithelial cysts as expected (Figures 1C and S1A). CCC organo-
ids displayed similar histological properties such as trabecular
and/or solid growth with cytoplasmic eosinophilia and highly
atypical cells like the poorly differentiated adenocarcinomas
from which they were derived (Figure 3A). Furthermore, some
cells within CCC organoids and their originating biopsies formed
intracytoplasmic lumens and produced Mucin, two character-
istic features of adenocarcinomas (Figures 3A and 4C). As ex-
pected, AFP expression was not detected in CCC tumor bi-
opsies and organoids (Figure 3B). All CCC organoid lines
expressed typical biliary markers such as KRT7 and KRT19
consistent with the expression pattern in the originating tumor
biopsies (Figure 3C).
The genetic analysis revealed hyper-mutator phenotypes in pa-
tient 16 (with the lymphoepithelioma-like cholangiocarcinoma)
and in patient 20 (Figure 5). Both tumors had >500 somatic muta-
tions. In patient 16, most of the mutations were maintained in the
organoids, whereas in patient 20, most were lost during the deri-
vation of organoids (Figure 5A). Interestingly, the vast majority of
somatic mutations in patient 16 were present in >80% of the tu-
mor cells, whereas in patient 20, most of them were found only
in subclonal cell populations (Figures S5 and S6; Table S4). It is
likely that most of the subclones in the originating tumor were
lost during the early steps of organoid culture. Patient 13 had 85
non-synonymous somatic mutations in the tumor. 36 were not
preserved in the organoids. Most of them were subclonal and
were not in bona fide cancer genes. The presumed cancer driver
mutations were preserved (Figure 5).Organoids and Their Originating Tumors
esent in each HCC biopsy and their derivative HCC organoids. The dashed line
imoto et al., 2016; Kandoth et al., 2013; Lawrence et al., 2014; Cancer Genome
rding to the legend, with hotspots (Chang et al., 2016; Gao et al., 2017) colored
n asterisk. Loss of heterozygosity of the wild-type allele of a mutated gene is
(Carter et al., 2012) are indicated by a black box.
somatic mutations in the tumors and their corresponding organoids, with the
n CCF.
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Figure 6. Differential Drug Responses in Patient-Derived HCC and CCC Organoids under Sorafenib Treatment
HCC and CCC organoids were exposed to sorafenib at the indicated concentration for 6 days. DMSO-treated tumor organoids were used as control.
(A) Representative bright-field images of sorafenib-treated HCC organoids (patient 5-B). Scale bar: 200 mm.
(B) Sorafenib reduces cell viability of HCC and CCC organoids in a dose-dependent manner. The dashed line represents the IC50. Data are presented as the
percentage of control DMSO-treated tumor organoids and are the mean of at least two independent experiments performed in duplicate.
(C) Differential IC50 (in mM) of HCC and CCC organoids shown as mean ± SEM. Patient numbers correspond to Table 1.We could successfully transplant the CCC organoids from pa-
tients 16 and 20 into immunodeficient mice. No xenografts could
be established from patient 13 despite repeated transplantation
attempts (Figure 4D). Surprisingly, histologic analysis of the
xenograft tissue revealed tumor areas with a desmoplastic
stroma reaction, a typical CCC feature that was also present in
the originating tumors, but not in the organoids due to the lack
of stromal cells (Figure 4C). This demonstrates that the capability
to induce a desmoplastic reaction and thus to reproduce the tu-
mormicroenvironment in vivo is intrinsically programmed in CCC
cells. Finally, Mucin-producing cells were also detected in the
xenograft tumors from CCC organoids (Figure 4C).
HCC and CCC Organoids Display Variable Sensitivity
to Sorafenib
In order to assess whether HCC-derived organoids would be a
suitable system for preclinical drug development, we treated
HCC organoid cultures with different concentrations of sorafenib
and monitored cell viability with CellTiter-Glo. The concentration
range was based on pharmacokinetic data from patients treated
with sorafenib (Nexavar) (Abou-Alfa et al., 2006). In our in vitro
assay, sorafenib reduced HCC organoid growth in a dose-
dependent manner (Figure 6A) with half-maximal inhibitory con-
centration (IC50) values that varied by 2.5-fold from 2.0 to 5.0 mM
(Figures 6B and 6C). Direct comparison of in vitro sorafenib ac-
tivity with the clinical response was not feasible because none
of the patients from whom we generated organoid cultureswere treated with sorafenib. The validation of the organoid
models as test systems for sorafenib response in vivowill require
the recruitment of many more patients and the generation of a
sizable number of additional HCC organoids derived from pa-
tients treated with sorafenib.
We also tested the efficacy of sorafenib on the three CCC
organoid lines. Notably, a CCC organoid derived from a rare
subtype of CCC (lymphoepithelioma-like CCC, patient 16) re-
sponded to sorafenib treatment in vitro with IC50 values compa-
rable with sorafenib-sensitive HCC organoids (Figures 6B and
6C). Sorafenib is not an established treatment for CCCs, but it
has recently been explored in a multicenter prospective study
that showed a modest effect on disease control rate (Luo
et al., 2017).
Taken together, our results demonstrate that organoids
derived from biopsies of primary liver cancers can be used to
test tumor-specific sensitivities to growth-inhibitory substances.
DISCUSSION
In vitro studies of HCC biology have so far been restricted to a
limited number of hepatoma and HCC cell lines. Most of them
have been established decades ago, and it is unclear how well
they represent the tumor biology of HCCs. HCC organoids over-
come many of the limitations of these cell lines. They can be
directly linked to a patient and to spatiotemporal information
such as a specific tumor nodule or a metastasis, or a specificCell Reports 24, 1363–1376, July 31, 2018 1371
time during the evolution of the cancer in a patient. Importantly,
we found that the organoids are polyclonal and thereby preserve
an important feature of the originating tumor that is linked to
cancer evolution, immune evasion, and resistance to oncostatic
and targeted therapies. Patient-derived tumor organoids have
recently been described for prostate (Gao et al., 2014), pancre-
atic (Boj et al., 2015), colorectal (van de Wetering et al., 2015),
breast (Sachs et al., 2018), and bladder cancer (Lee et al.,
2018). Broutier et al. (2017) reported the establishment of orga-
noid cultures derived from resections of primary liver cancers.
In our study, we report the establishment of organoids from
HCC needle biopsies, overcoming a major limitation of ap-
proaches that use surgically resected HCC specimens. Indeed,
surgical resection is a treatment option for the minority of HCC
patients with early tumor stages and/or a non-cirrhotic liver.
These patients usually do not receive systemic therapies. In
contrast, biopsies can also be obtained from patients with inter-
mediate and advanced tumor stages who frequently receive
systemic therapies. The use of biopsies therefore allows for
establishment of an organoid biobank that reflects the entire
spectrum of HCCs. Furthermore, such a biobank can be en-
riched to include clinical data such as response to treatments,
resistance development, and survival.
The use of tumor biopsies also allowed a comparison of tumor
and organoids. Of note, several biopsies from the same location
in a tumor could be obtained using an ultrasound-guided coaxial
biopsy technique. The resulting set of biopsies is mutually repre-
sentative and can be used for multidimensional analysis. We
found a striking similarity between originating tumors and orga-
noids in routine histopathology and immunostaining analysis.
Moreover, the individual tumor features were also maintained af-
ter transplantations into immunodeficient mice. We conclude
that these morphological features are inherently programmed
in the tumor cells and are not subject to the tumor environment
(Figure 3). Furthermore, the expression of well-established
HCC biomarkers, as well as the mutational landscape, is pre-
served in HCC organoids (Figure 5). When compared with the
previous study by Broutier et al. (2017) that used resected spec-
imens, our tissue collection procedure allowed for collection of
non-tumor liver biopsies at a site distant from the tumor nodule(s)
to generate non-tumor liver organoids for all patients and to
perform patient-specific normalization of our genomic and tran-
scriptomic data.
In our series of tumor biopsies we derived HCC organoids with
a success rate of 26% (per number of biopsies) and 33% (per
number of patients). This is lower compared with the reported
success rates for pancreatic cancer (75%–83%) (Boj et al.,
2015) and colorectal cancers (90%) (van de Wetering et al.,
2015), possibly because the cell of origin of HCCs, the hepato-
cytes, lack features of epithelial stem cells that favor their prop-
agation in the organoid culture system.
However, our success rate is in line with a recent study by
Pauli et al. (2017) reporting an average success rate of 38%
across different tumor types. In their report, the authors used
small-needle biopsies as tumor tissue source in some of their
cases and conclude that the major limitation to establish tumor
organoids was the insufficient amount of fresh tissue. Indeed,
given the limited amount of starting material (needle biopsies),1372 Cell Reports 24, 1363–1376, July 31, 2018we could not set up a systematic screening of different culture
systems to improve the derivation efficiency. Broutier et al.
(2017) tried to optimize the culture conditions for the generation
of liver cancer organoids by removing some of the growth factors
contained in the original media recipe in order to reduce the
outgrowth of normal liver organoids. However, the changes
they performed did not result in organoid generation from all of
their tumor specimen. Based on informed guesses, we tried to
optimize culture conditions in a small number of cases where
we hadmore than one biopsy as a startingmaterial. For example,
we removed compounds with potential negative effects on HCC
proliferation such as Forskolin, N-acetyl-L-cysteine, nicotin-
amide, and HGF from the medium, and added FGF19, a factor
with potential growth-promoting effects for HCCs. However,
these limited efforts did not result in the establishment of addi-
tional HCC organoid lines. Nevertheless, we anticipate that addi-
tional efforts in refining the media recipes (Fujii et al., 2016), and
possibly also the use of tailored 3D matrices (Gjorevski et al.,
2016), to specifically accommodate the growth of HCC- and
CCC-derived organoids, respectively, will improve the success
rate. This would be a prerequisite for using HCC organoids as
patient-specific in vitro models of drug sensitivity with the aim
to inform treatment decisions on an individualized basis. Of
note, the time required to expand the organoid cultures for
drug testing is presently 4–12weeks. Urgent treatment decisions
will therefore not rely on in vitro drug testing of individual patient-
derived organoids, even if the success rate should be much
higher in the future. More realistically, systematic drug testing
in a large enough number of HCC organoids will allow to predict
patient responses to different treatments based on matching
molecular characteristics of tumor biopsies and organoids (Drost
and Clevers, 2018).
One other potential reason for the limited success rate could
be that HCC organoids can be generated only from a restricted
subset of HCCs. We therefore compared clinical, histopatholog-
ical, and molecular features of HCCs that could be propagated
as organoids with HCCs that could not. No significant correla-
tions were found with a comprehensive set of clinical data
(Figure 2A). Indeed, HCC organoids could be derived from pa-
tients with all major underlying liver diseases and different
clinical stages of HCC, demonstrating the potential of the orga-
noid technique for building up larger biobanks representing the
entire clinical spectrum of liver cancer. On the other side, there
was a significant correlation with one of the histopathological
features, the Edmondson grade of the tumors. HCC organoids
could only be generated from poorly differentiated tumors. It is
conceivable that the generation of HCC organoids requires a
cell proliferation rate threshold that is not reached in highly differ-
entiated, slow-growing Edmondson grade I and II tumors. This is
supported by our finding that the proliferation marker KI-67 and
cell-cycle pathway genes were upregulated in tumor biopsies
with successful organoid derivations compared with those
where organoids could not be generated (Figures S2A and
S2B; Table S5). These data are in line with those from Broutier
et al. (2017) showing that onlymoderately to poorly differentiated
HCCs with a KI-67 index >5% were able to generate organoids.
Of note, other histopathological features in our HCC cohort such
as the percentage of viable tumor cells in the biopsy, the amount
of stroma or immune cell infiltration, the growth pattern of the tu-
mor, or the degree of tumor necrosis were not correlated with
success or failure of organoid derivation (Table S1).
Finally, to investigate whether HCC organoids can only be
derived from a specificmolecular subtype of HCC, we compared
transcriptome data of all of our tumor biopsies with a reference
set of poorly differentiated HCCs from the TCGA database (Can-
cer Genome Atlas Research Network, 2017). We found no
enrichment of our samples in distinct subclasses of HCCs (Fig-
ure 2C). We conclude that the organoid technique described in
this manuscript allows the generation of a heterogeneous tumor
organoid biobank that is a representative sample of the entire
clinical, histopathological, and molecular spectrum of poorly
differentiated HCCs.
The analysis of the relative frequency of non-synonymous so-
maticmutations in the tumor biopsies and the HCCorganoids re-
vealed the expected preservation of highly prevalent putative
driver mutations. However, it also revealed that mutations pre-
sent in only a subset of tumor cells, i.e., subclone-specific muta-
tions, were also preserved, often with surprisingly similar relative
frequencies between tumor biopsies and HCC organoids (Fig-
ures 5C and S3–S6; Table S4). This is somewhat unexpected,
because it does not support a model where tumor organoids
are derived from a single cancer stem cell. There is compelling
evidence that intestinal organoids can be derived from single
LGR5-positive stem cells (Clevers, 2016). For liver-derived orga-
noids, this is less clear (Huch et al., 2015). It remains to be inves-
tigated whether the stem cell model is applicable for HCC tumor
organoids. In any case, the coexistence of different cancer cell
subclones with different sensitivities to targeted therapies is an
important factor linked to therapy failure (Fisher et al., 2013).
Therefore, we believe that organoid models will play a major
role in the development of novel drug candidates able to target
different genetic subclones within tumors to impede the selec-
tion of resistant cells present at low frequencies at therapy onset.
Furthermore, the knowledge of the patient-specific genetic
background will allow the unique opportunity to correlate
response to specific drugs with putative driver mutations, a pre-
requisite for future efforts of personalized management of tar-
geted therapies.EXPERIMENTAL PROCEDURES
Human Tissues and Biopsy Procedure
Human tissueswere obtained from patients undergoing diagnostic liver biopsy
at the University Hospital Basel. Written informed consent was obtained from
all patients. The study was approved by the ethics committee of the north-
western part of Switzerland (Protocol Number EKNZ 2014-099). Ultrasound
(US)-guided needle biopsies were obtained from tumor lesion(s) with a coaxial
liver biopsy technique that allows taking several biopsy samples through a sin-
gle biopsy needle tract. After local anesthesia, the introducer needle was
advanced 2–3 cm into the liver parenchyma. In case of a focal lesion, the nee-
dle was positioned precisely at the tumor border. The trocar of the introducer
needle was removed, and up to five cylindrical biopsies of 1 mm diameter
and 10–30 mm in length were obtained with an automatic spring-loaded bi-
opsy needle (BioPince). The introducer needle was kept in place during the
entire procedure to ensure that all specimens came from the same area of
the tumor. One cylinder was fixed in formalin and paraffin-embedded for
diagnosis and staging. Additional cylinders were immediately snap-frozen in
liquid nitrogen for later use in DNA and RNA extraction or embedded inO.C.T. (Tissue-Tek) and frozen using standard procedures. For organoid gen-
eration, biopsy pieces were placed in advanced DMEM/F-12 (GIBCO). For
control tissue, all patients who underwent US-guided HCC biopsy also got a
biopsy of the liver parenchyma at a site distant from the tumor. The needle tract
was filled with absorbable gelatin sponge before removal of the introducer
needle.
Organoid Culture
Tumor biopsy fragments designated for organoid generation typically
measured 1 mm 3 5–10 mm corresponding to a volume of 3.9–7.9 mm3.
They were transported to the laboratory on ice and further processed for orga-
noid generation within 20 min after collection. For tumor organoid generation,
biopsies underwent a limited digestion to small-cell clusters.We avoided com-
plete digestion into single cells because it has been reported that preservation
of cell-cell contacts enhances derivation efficiency (Kondo et al., 2011). Tumor
tissue was minced and shortly (maximum [max.] 2–4 min) digested with
2.5 mg/mL collagenase IV (Sigma), 0.1 mg/mL DNase (Sigma) at 37C. The
yield of the procedure varied because of differences in the size of the tumor bi-
opsy available for the generation of organoids and the variable content of
viable tumor cells in the biopsies. Cell clusters were then seeded into reduced
growth factor BME2 (Basement Membrane Extract, Type 2; Amsbio). After
polymerization of BME2, expansion medium (Huch et al., 2015) was added
to the cells. The composition is advanced DMEM/F-12 (GIBCO) supplemented
with 1:50 B-27 (GIBCO), 1:100 N-2 (GIBCO), 10 mM nicotinamide (Sigma),
1.25 mM N-acetyl-L-cysteine (Sigma), 10 nM [Leu15]-gastrin (Sigma), 10 mM
forskolin (Tocris), 5 mM A83-01 (Tocris), 50 ng/mL EGF (PeproTech),
100 ng/mL FGF10 (PeproTech), 25 ng/ml HGF (PeproTech), 10% RSpo1-
conditioned medium, (homemade), and 30% Wnt3a-conditioned medium
(homemade). In the few cases for which enough biopsymaterial was available,
we tried an adapted version of the culture medium in comparison with the
normal one. The adapted medium lacked some of the original components re-
ported to have a negative effect on HCC cell proliferation (forskolin, N-acetyl-
L-cysteine, nicotinamide, HGF) and contained FGF19 because of the frequent
amplification of the FGF19 gene detected in HCCs and its positive effect on
proliferation of HCC cells. However, these attempts did not result in the
establishment of additional HCC organoid lines. Organoid cultures from non-
tumor liver biopsies were generated as previously described (Huch et al.,
2015). Tumor organoids were passaged after dissociation with 0.25%
Trypsin-EDTA (GIBCO). Non-tumor liver organoids were passaged by me-
chanical dissociation through a fire-polished Pasteur-pipette or incubation in
0.25% Trypsin-EDTA (GIBCO) for 2 min. Cryovials were prepared at regular in-
tervals by dissociating organoids and resuspending in Recovery Cell Culture
Freezing Medium (GIBCO) prior to freezing.
We could prepare frozen stocks of early (%P4) passages from all the samples
that yielded tumor organoids. All organoid lines could be kept in long-term
cultures with regular splitting for at least 1 year. All organoid cultures were regu-
larly tested for Mycoplasma contamination with the MycoAlert Mycoplasma
Detection Kit (Lonza) according to the manufacturer’s instructions.
Organoid Xenotransplantation
All experiments involving organoid transplantations into mice were performed
in strict accordance with Swiss law and were approved by the ethics commit-
tee of the northwestern part of Switzerland (Protocol Number EKNZ 2014-099)
and the Animal Care Committee of the Canton Basel-Stadt, Switzerland.
Tumor organoids, corresponding to 1 3 106 cells, were released from BME2
by incubating in Cell Recovery Solution (Corning), resuspended in 100 mL
50:50 (v/v) BME2:expansion medium, and injected subcutaneously into immu-
nodeficient non-obese diabetic (NOD) severe combined immunodeficiency
(SCID) gamma (NSG)mice (The Jackson Laboratory) at young age (6–8weeks).
Paired non-tumor liver organoids were used as negative control.
Histology and Immunohistochemistry
Liver biopsies from tumoral and non-tumor tissue, as well as tumor organoid
xenografts, were fixed in 4% phosphate-buffered formalin and embedded in
paraffin using standard procedures. Additional biopsies were also embedded
in O.C.T. (Tissue-Tek) and frozen using standard procedures. Tumor organo-
idswere released fromBME2 by incubating in Cell Recovery Solution (Corning)Cell Reports 24, 1363–1376, July 31, 2018 1373
following the manufacturer’s instructions. Organoids were then fixed in freshly
prepared 4% formalin solution in PBS for 30min at room temperature following
dehydration and paraffin embedding. Sections were subjected to H&E,
Masson’s trichrome, Alcian blue-periodic acid-Schiff (PAS), as well as immu-
nohistochemical staining, using standard procedures. Histopathological eval-
uation was assessed by two board-certified pathologists (M.S.M. and L.M.T.).
Tumors were classified based on architecture and cytological features, and
graded according to the Edmondson grading system (Edmondson and
Steiner, 1954).
For immunohistochemistry, the following primary antibodies were used for
automated staining on a Benchmark XT device (Ventana Medical Systems):
AFP (Ventana catalog number [Cat. No.] 760-2603), GS (Ventana Cat. No.
760-4898), GPC3 (Ventana Cat. No. 790-4564), HSP70 (Biocare Medical
CM407A), Keratin 7 (Ventana Cat. No. 790-4462), Keratin 19 (Ventana Cat.
No. 760-4281), and KI-67 (Ventana Cat. No. 760-4286).
Drug Treatment
Sorafenib tosylate (Cat. No. S-8502) was purchased from LC Laboratories,
dissolved in DMSO at 10 mM aliquots, and stored at20C. Tumor organoids
were plated at a density of 53 103 cells in 15 mL BME2 droplets in order to form
organoids. At day 6, sorafenib was added to the medium, and cell viability was
measured after 6 days using CellTiter-Glo 3D reagent (Promega). Lumines-
cence was measured on a Synergy H1 Multi-Mode Reader (BioTek Instru-
ments). Results were normalized to vehicle (=100% DMSO). Curve fitting
was performed using Prism (GraphPad) software and the nonlinear regression
equation. All experiments were performed at least two times in duplicate.
Results are shown as mean ± SEM.
DNA and RNA Extraction
Genomic DNA from tumor organoids was extracted using the DNeasy Blood &
Tissue kit (Qiagen) following the manufacturer’s instructions. Genomic DNA
and total RNA from biopsies were extracted using the ZR-Duet DNA and
RNA MiniPrep Plus kit (Zymo Research) following the manufacturer’s instruc-
tions. Prior to extraction, biopsies were crushed in liquid nitrogen to facilitate
lysis. Extracted DNA was quantified using the Qubit Fluorometer (Invitrogen).
Whole-Exome Sequencing
DNA extracted from eight HCC biopsy-derived organoid lines (patients 1, 2,
5-A, 5-B, 9, 12-I, 12-II, and 25), three CCC biopsy-derived organoid lines (pa-
tients 13, 16, and 20), the corresponding original biopsies, and the control
paired non-tumor biopsies were sequenced using whole-exome sequencing.
The eight HCC biopsies were derived from six patients and for three of the bi-
opsies, early- and late-passage organoids were profiled (Table S2). The tumor
biopsy sample corresponding to patient 1 had to be excluded from further an-
alyses because of low tumor cell content in the biopsy. Whole-exome capture
was performed using the SureSelectXT Clinical Research Exome (Agilent) plat-
form according to the manufacturer’s guidelines. Sequencing was performed
on an Illumina HiSeq 2500 at the Genomics Facility Basel according to the
manufacturer’s guidelines. Paired-end 101-bp reads were generated.
Whole-Exome Sequencing Analysis
Sequence reads were aligned to the reference human genome GRCh37 using
Burrows-Wheeler Aligner (BWA, v0.7.12) (Li and Durbin, 2009). Local realign-
ment, duplicate removal and base quality adjustment were performed using
the Genome Analysis Toolkit (GATK, v3.6) (McKenna et al., 2010) and Picard
(http://broadinstitute.github.io/picard/). Somatic single nucleotide variants
(SNVs) and small insertions and deletions (indels) were detected using MuTect
(v1.1.4) (Landau et al., 2013) and Strelka (v1.0.15) (Saunders et al., 2012),
respectively. We filtered out SNVs and indels outside of the target regions:
those with variant allelic fraction (VAF) of <1% and/or those supported by <3
reads. We excluded variants for which the tumor VAF was <5 times that of
the paired non-tumor VAF, as well as those found at >5% global minor allele
frequency of dbSNP (build 137). We further excluded variants identified in at
least two of a panel of 123 non-tumor samples, including the 4 non-tumor sam-
ples included in the current study, captured and sequenced using the same
protocols using the artifact detection mode of MuTect2 implemented in
GATK. All indels were manually inspected using the Integrative Genomics1374 Cell Reports 24, 1363–1376, July 31, 2018Viewer (Thorvaldsdo´ttir et al., 2013). To account for the presence of somatic
mutations thatmay be present below the limit of sensitivity of somaticmutation
callers, we used GATK Unified Genotyper to interrogate the positions of all
unique mutations in all samples from a given patient to define the presence
of additional mutations.
Allele-specific CNAs were identified using FACETS (v0.5.5) (Shen and Se-
shan, 2016) as previously described (Piscuoglio et al., 2016), which performs
a joint segmentation of the total and allelic copy ratio and infers allele-specific
copy number states. Somatic mutations associated with the loss of the wild-
type allele (i.e., loss of heterozygosity [LOH]) were identified as those where
the lesser (minor) copy number state at the locus was 0. All mutations on
chromosome X in male patients were considered to be associated with
LOH. All gene amplifications and homozygous deletions were visually in-
spected using plots of raw log2 and allelic copy ratios. Copy number states
were collapsed to the gene level based on the median values to coding
gene resolution based on all coding genes retrieved from the Ensembl
(release GRCh37.p13).
The CCF of each mutation on the autosomes was inferred using the number
of reads supporting the reference and the alternate alleles, and the segmented
log2 ratio fromWES as input for ABSOLUTE (v1.0.6) (Carter et al., 2012). Solu-
tions fromABSOLUTEweremanually reviewed as recommended (Carter et al.,
2012; Landau et al., 2013). Amutation was classified as clonal if its clonal prob-
ability, as defined by ABSOLUTE, was >50%, or if the upper bound of the 95%
confidence interval of its CCF crosses 1.Mutations that did notmeet the above
criteria were considered subclonal.
Cancer genes were annotated according to the cancer gene lists described
by Kandoth et al. (2013) (127 significantly mutated genes), Lawrence et al.
(2014) (Cancer5000-S gene set), Fujimoto et al. (2016), or the TCGA (Cancer
Genome Atlas Research Network, 2017). Mutations affecting hotspot residues
(Chang et al., 2016; Gao et al., 2017) were annotated. Pathogenicity of
missense mutations was predicted using CHASM (liver cancer predictor, viral
or non-viral as appropriate) (Carter et al., 2009) and FATHMM (cancer predic-
tor) (Shihab et al., 2013).
Decomposition of the mutational signature was performed using
deconstructSigs (Rosenthal et al., 2016), based on the set of 30 mutational
signatures (‘‘signature.cosmic,’’ based on the signatures at https://cancer.
sanger.ac.uk/cosmic/signatures; Alexandrov et al., 2013; Nik-Zainal et al.,
2016).
RNA-Seq
RNA extracted from all HCC biopsies (n = 38; Table S1) and the paired non-tu-
mor biopsies were sequenced using RNA-seq. Tumor samples corresponding
to patients 1, 7-B (C959), 15-B, and 29-A had to be excluded from further an-
alyses because of low tumor cell content in the biopsy. 200 ng total RNA was
used for RNA-seq library prep with the TruSeq Stranded Total RNA Library
Prep Kit with Ribo-Zero Gold (Illumina) according to manufacturer’s specifica-
tions. SR126 sequencing was performed on an Illumina HiSeq 2500 using v4
SBS chemistry at the Genomics Facility Basel according to the manufacturer’s
guidelines. Primary data analysis was performed with the Illumina RTA version
1.18.66.3.
RNA Sequencing Analysis
Sequence reads were aligned to the human reference genome GRCh37
by STAR (Dobin et al., 2013) using the two-pass approach. Transcript quanti-
fication was performed using RSEM (Li and Dewey, 2011). For unsupervised
cluster analysis, we retrieved the TCGA Liver dataset RNA-seq data
(‘‘V2_MapSpliceRSEM’’) from the Genomics Data Commons Data Portal (Can-
cer Genome Atlas Research Network, 2017). We performed gene-level upper
quartile normalization of the combined dataset to the fixed threshold 1,000 as
described in the TCGA study (Cancer GenomeAtlas ResearchNetwork, 2017).
Genes whose expression was quantified to zero by RSEM (Li and Dewey,
2011) in >75%of the samples were removed. RSEM valueswere subsequently
log2-transformed, adding 0.5 to RSEM values prior to transformation. To iden-
tify genes with variable expression for clustering, genes with standard devia-
tion < 2 were excluded. Batch correction using the edgeR package (Niko-
layeva and Robinson, 2014) was performed to correct for systematic biases
between the datasets. Cluster analysis was performed using hierarchical
clustering using the Ward method and with a 1-Pearson correlation distance
(Cancer Genome Atlas Research Network, 2017).
For the TCGAHCC cohort (Cancer Genome Atlas Research Network, 2017),
images of diagnostic H&E slides were retrieved from the cbioportal (http://
www.cbioportal.org; accessed December 2017) (Gao et al., 2013) and re-
viewed by two expert hepato-pathologists (M.S.M. and L.M.T.) according to
the Edmondson grading system (Edmondson and Steiner, 1954) for compari-
son purposes. Differential expression analysis between biopsies that did or did
not yield organoids was performed using the edgeR package (Nikolayeva and
Robinson, 2014). Specifically, genes with <1 count per million in more than five
HCC biopsies were removed. Normalization was performed using the ‘‘TMM’’
(weighted trimmed mean) method, and differential expression was assessed
using the quasi-likelihood F-test.
Statistical Analysis
p values were calculated with Fisher’s exact test or Mann-Whitney test using
Prism (GraphPad) software, as specified in the Results section and in the figure
legends.
Data and Software Availability
Sequence data have been deposited at the European Genome-phenome
Archive (EGA), which is hosted by the EBI and the CRG, under accession num-
ber EGAS00001003115.
SUPPLEMENTAL INFORMATION
Supplemental Information includes eight figures and five tables and can be
found with this article online at https://doi.org/10.1016/j.celrep.2018.07.001.
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